

October 4, 2021

Press release

EFPIA Japan
(European Federation of Pharmaceutical Industries and Associations)

EFPIA Japan Patient Organization Support Program “PASE” Fourth “PASE AWARD” winners decided

TOKYO – 30 September 2021 – EFPIA Japan (European Federation of Pharmaceutical Industries and Associations) presented its Fourth PASE AWARD, selecting patient groups that particularly contribute to the evolution of Japan’s patient advocacy and offering grants totalling 1.45 million yen. For the fourth year, “addressing the challenges of the COVID-19 pandemic and creating connected, supportive societies” was selected as the application theme. Recruitment of patient organizations’ action plans started in May and applications from a total of 14 patient organizations were received by July 16. This year the “Grand Award” has been given to two groups, and the “Honor Award” has been given to three groups as below.

Fourth PASE AWARD winning organizations

Award	Award winning organization	Overview of application / proposal	Grant (JPY)
Grand Award	NPO Keep Mama Smiling	Expand support for long-term inpatient caregivers who cannot leave the ward due to Covid19 infection prevention	500,000
Grand Award	Institute Esophageal Cancer Survivors Sharings	Activities to raise awareness of correct knowledge of esophageal cancer and examination and prevention	500,000
Honor Award	Certified NPO Breast Cancer Patient Association Kirara	Disseminate information to promote social understanding of cancer	150,000
Honor Award	NPO Sagamihara Allergy Association	Provide information for balancing treatment with school/work and distribute stickers to notify the public of allergic symptoms	150,000
Honor Award	NPO PanCAN Japan	Awareness activities to promote early access to the treatment of pancreatic cancer	150,000

EFPIA Japan Chair Takahiko Iwaya said, "I would like to thank all the patient organizations that applied for the Fourth PASE AWARD. Patient group activities to support patients are becoming more and more important in the face of various restrictions due to the pandemic caused by COVID-19 since last year. All the proposals received this time were very meaningful especially in these difficult times, and the decision on the Grand Prize was extremely difficult. EFPIA Japan will continue to support the activities of these patient groups to ensure that patients in Japan have access to the latest medical care."

About the EFPIA Japan Patient Organization Support Program “PASE”

“PASE (Patient Advocacy Support by EFPIA Japan)” is a patient organization support program established in 2017 with the goal of realizing the patient-centered thinking of EFPIA Japan. PASE was conceived to further encourage patient group activities in Japan, and to support the healthcare environment surrounding patients to evolve, so that it better reflects patients’ voices and patient needs. As part of PASE, EFPIA Japan decided to conduct the PASE AWARDS, in which grants of 1.45 million yen this year will be awarded to organizations that contribute to the evolution of patient advocacy (activities to protect patient rights).

About the Fourth “PASE AWARD”

Due to the fight against the novel virus that has been raging since last year, we are now required to restrict various aspects of our lives. Under such circumstances, many patients feel increasingly lonely, and it has become even more important to improve the understanding of those around us, to connect with society and other patients, and to communicate smoothly with doctors. For the Fourth PASE AWARD, in light of the potential impact of these environmental changes on patients, “addressing the challenges of the COVID-19 pandemic and creating connected, supportive societies” was selected as the application theme. The Fourth PASE AWARD invited active patient groups with legal entity status to submit plans between May 12 and July 16 to utilize the PASE grant in Japan. The draft plans were reviewed and selection was based on four evaluation criteria: “Having a clear purpose as a patient group and clear goals with KPIs”, “Showing concrete deliverables for achieving purpose in past activities”, “Having a specific implementation plan of activity for using grants (including how to use grants)”, “Being able to cooperate in disseminating the results of activities using grants (Allowing for posting on the EFPIA Japan website, notification and reporting on their own website)”. The two organizations that won the Grand Award will each be offered a grant of 500,000 yen and be invited to attend the presentation ceremony on October 13, 2021. The three groups that won the Honor Award will be offered a grant of 150,000 yen. Details of the Fourth PASE AWARD presentation ceremony will be shared separately.

The Fourth PASE Final Selection Committee Members

- Mr. Takahiko Iwaya, EFPIA Japan Chair (Sanofi K.K.)
- Mr. Yoshiaki Aono, EFPIA Japan Vice Chair (Nippon Boehringer Ingelheim Co., Ltd.)
- Mr. Paul Lirette, EFPIA Japan Board Member (GlaxoSmithKline K.K.)
- Mr. Kana Matsumura, EFPIA Japan Governance and Legal Committee Chair (Nippon Boehringer Ingelheim Co., Ltd.)
- Mr. Takeo Nakayama (Kyoto University Faculty of Medicine, Professor of Health Informatics)

About EFPIA Japan

Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceutical companies operating in Japan. In 2020, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to

“Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About the European Federation of Pharmaceutical Industries and Associations (EFPIA)

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world

Details can be found below.

<http://efpia.jp/> (EFPIA Japan)

<http://www.efpia.eu> (EFPIA)

Inquires to :

Jun Saito
EFPIA Japan Public Relations Sub-committee in
charge of PASE
1-23-1 Toranomon, Minato-ku, Tokyo
105-6333
Toranomon Hills Mori Tower
Novartis Pharma K.K.
TEL: 080-7566-8852
Mail: jun.saito@novartis.com

Naomi Sakai
EFPIA Japan Patient committee in charge of
PASE
2-1-1 Osaki, Shinagawa-ku, Tokyo
141-6017
ThinkPark Tower
Nippon Boehringer Ingelheim Co., Ltd.
TEL: 03-6417-2489
Mail: naomi.sakai@boehringer-ingelheim.com